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John T. O’Brien1*† and Karl Herholz2†Abstract
In vivo imaging of brain amyloid using positron emission tomography (PET) scanning is widely used in research
studies of dementia, with three amyloid PET ligands being licenced for clinical use. The main clinical use of PET is
to help confirm or exclude the likely diagnosis of Alzheimer’s disease in challenging cases, where diagnostic
uncertainty remains after current clinical and investigative work up. Whilst diagnostically valuable in such select
cases, much wider clinical adoption, especially for very early disease, will be limited by both cost and the lack of a
currently effective disease-modifying treatment that requires such early case identification. The use of amyloid
imaging to appropriately stratify subjects for prognostic studies and therapeutic trials should increase the efficiency
and potentially shorten the time of such studies, and its use combined with other biomarkers and genetics will likely
lead to new ways of defining and classifying the dementias.
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Recent advances in brain imaging have transformed the
way we think about, understand, and characterise
Alzheimer’s disease and other dementias. Amongst these,
amyloid imaging has moved rapidly from a highly select
carbon-based research tool available only in centres with
cyclotrons, to full commercialisation, with three fluori-
nated amyloid PET tracers (florbetapir, florbetaben, and
flutemetamol). These advances have allowed wider distri-
bution, with the technique now being licenced in many
countries for clinical use [1]. The ability to more directly
visualise, in vivo, aspects of pathology in the brain, in this
case amyloid deposition previously only possible at aut-
opsy, undoubtedly represents a significant step forwards.
All three amyloid imaging ligands have been tested in
well-conducted, blinded studies and all demonstrate a
robust correlation with brain amyloid deposition [2–4],
particularly with neuritic plaques, though they also bind
to amyloid elsewhere (for example, in blood vessels). It is
unclear whether one imaging agent has advantages over
others [5]; they are at slightly different points on the
development pathway, have adopted different methods* Correspondence: john.obrien@medschl.cam.ac.uk
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creativecommons.org/publicdomain/zero/1.0/for analysing and reading scans (flutemetamol uses
colour, florbetaben and florbetapir provide greyscale im-
ages) and they have slightly different tracer kinetics in
terms of how scan time relates to time of injection. This
commentary considers issues surrounding their likely use
in clinical practice.Use of amyloid imaging
Amyloid imaging has been rapidly adopted by the re-
search community, for obvious reasons, including deter-
mining when and how amyloid deposition builds up in
the brain, how it relates to clinical symptoms and pro-
gression, and defining its temporal relationships with
other key pathological aspects of the disease such as tau
deposition, structural brain atrophy, and neuroinflam-
mation. These questions have been the focus of several
large studies which have advanced our understanding of
the disease. For example, amyloid deposition appears an
early event, possibly occurring up to 20 years before
clinical symptoms [6]. However, nothing in clinical
medicine is straight forward, and Alzheimer’s disease is
no exception. So the relationship between amyloid
and the other characteristic pathological hallmark of
Alzheimer’s disease, tau pathology, still remains uncertain.
Whilst amyloid is widely thought to be “upstream” of tau
deposition, tau pathology is known to relate more closelyccess article distributed under the terms of the Creative Commons Attribution
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that amyloid deposition occurs first, recent studies have
suggest that some people with Alzheimer’s disease may
present with more tau-focused neurodegenerative change
prior to evidence of substantial amyloid deposition, at least
on brain imaging [7]. There remain issues to be clarified
regarding how best to analyse images for research [8], as
whilst for clinical reporting a “positive or negative” scan
reporting approach has been adopted, which does
not reflect the reality of borderline changes some-
times seen in clinical practice. Whilst such an all or
none approach is arguably suitable for characterising
pathological change in people with established de-
mentia, it is unlikely to be appropriate for defining
early in vivo changes in all situations.
In contrast to its embrace by the research community,
clinical use of these ligands has been relatively limited to
date, with healthcare and insurance authorities reluctant
to provide clinical reimbursement because of uncertainty
and debate over the perceived “added value” of amyloid
imaging over current diagnostics, especially in the ab-
sence of an available disease-modifying therapy. This
debate will continue while more evidence accumulates
[9], though the benefits of an accurate early diagnosis
are very highly valued by patients and carers and an ac-
curate diagnosis remains at the heart of appropriate
management, enshrined in the dementia plans of many
countries [10]. There will be clinical situations where
amyloid imaging is likely to be especially helpful. These
have been highlighted through consensus groups and ap-
propriate use criteria have been published [11]. There is
an age-related increase in amyloid positivity in control
subjects [12], and most likely also in patients suffering
from non-Alzheimer’s diseases. Thus, supporting an
Alzheimer’s diagnosis with positive amyloid imaging will
be more robust in younger subjects and therefore the
suggestion of its preferred use in younger subjects is not
ageist, but evidence based. Some distinctions, such as
between Alzheimer’s disease and frontotemporal demen-
tia (which is not associated with amyloid deposition), are
likely to be more highly informative [13], especially
when presenting with progressive language impairment.
It is less useful for distinguishing Alzheimer’s disease
from Lewy body dementia, since the latter can also
be associated with amyloid deposition [14] and other
established biomarkers for this differentiation already
exist [15].
However, it is likely to be a mistake to apply amyloid
imaging as a diagnostic tool for our currently accepted
categorical classification of disease, without accepting
that this will almost certainly change over the next
decade. Recent revisions of diagnostic criteria for
Alzheimer’s disease propose inclusion of amyloid im-
aging, along with other biomarkers, to help diagnose“prodromal” disease [16], or to increase certainty of the
clinical diagnosis [17]. These changes remind us that
diagnostic classifications evolve with advancing know-
ledge. Different classification domains already exist in de-
mentia: clinical, pathological, and genetic. They overlap
but do not correlate in a one-to-one fashion, and we
should not expect complete correspondence in the fu-
ture. A good review on the spectrum of diseases, patho-
logical proteins, and genetic mutations has recently been
provided by Villemagne et al. [18]. Thus, demonstrations
of limited correspondence between clinical diagnosis and
amyloid imaging, as for instance in the recent publication
by Mendez et al. [19], should not be taken as evidence
for misdiagnosis by clinical or imaging assessment. It
rather demonstrates that we are just at the beginning of
gaining better insight into the spectrum of dementia. Of
course, the most relevant classification will ultimately be
one that will successfully guide therapy, and we are still
struggling with that. Progress will depend on conducting
a broad range of clinical trials. We should learn in that
respect from oncology, where accurate multidimensional
classification of disease is already a reality, mostly based
on the progress of molecular analysis of blood and tissue
markers. We have that possibility in the brain only to a
very limited extent (via cerebrospinal fluid), making
molecular imaging markers even more important. The
finding of a recent failed anti-amyloid study, namely that
one-third of subjects entered were amyloid PET negative
to begin with [20], supports the current view that an im-
portant application of amyloid PET is the appropriate
stratification of subjects for therapeutic trials.Conclusions
The development of amyloid imaging represents an im-
portant step change in our ability to characterise and as-
sess patients with cognitive impairment and dementia.
Currently, there are clinical situations where it promises
to make an important contribution to enhancing diag-
nostic accuracy. However, the real advance of amyloid
imaging is likely to be not just about improving diagnos-
tics, but about appropriately selecting subjects at an
early stage for disease-modifying therapies once these
become available. In addition, as part of a wider bio-
logical profiling of a complex disease, it promises to
drive forwards new ways of understanding and classify-
ing the dementia.Abbreviations
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